{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T21:50:28Z","timestamp":1763761828728,"version":"3.45.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The modified multiplier of the SES-CD (MM-SES-CD) has been shown to predict future endoscopic healing (EH) in patients with Crohn\u2019s disease. The purpose of this study was to validate baseline MM-SES-CD categories of severity and determine their prognostic value for predicting 1-year EH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Participants in the SEAVUE trial (n\u2005=\u2005386) were classified based on baseline endoscopic disease severity using MM-SES-CD cut-offs as mild (\u2265\u200522.5 to\u2005&amp;lt;\u200531), moderate (\u2265\u200531 to\u2005&amp;lt;\u200545), and severe (\u2265\u200545) disease. The primary outcome was achieving 1-year endoscopic healing (EH) as measured by the MM-SES-CD score (&amp;lt;\u200522.5). Secondary outcomes included clinical and biochemical remission at 1 year based on patient-reported outcomes and fecal calprotectin (FCP)(&amp;lt;\u2005250 mcg\/g).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>MM-SES-CD\u2005&amp;lt;\u200522.5 at 1 year was achieved in 62.0% of patients with baseline mild endoscopic disease, 48.6% with moderate disease, and 33.8% with severe disease (P\u2005&amp;lt;\u2005.001). A similar trend was observed for patient-reported outcome (PRO-2) clinical remission, which was reached in 78.9% of patients with baseline mild endoscopic disease, 72.9% of those with moderate, and 66.2% of those with severe disease (P\u2005=\u20050.09). The likelihood of fecal calprotectin (FCP) remission was significantly associated with baseline endoscopic disease severity (P\u2005=\u2005.008).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Baseline MM-SES-CD-based cutoffs for endoscopic disease severity show prognostic value for the likelihood of achieving 1-year EH, PRO2 remission, and FCP remission. These findings suggest that the MM-SES-CD can be used both to measure baseline endoscopic disease severity and predict outcomes at 1 year in patients with moderate to severe CD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izaf137","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T07:52:08Z","timestamp":1749628328000},"page":"3103-3111","source":"Crossref","is-referenced-by-count":1,"title":["Validation of the Modified Multiplier of SES-CD (MM-SES-CD) to Predict Endoscopic Healing in Crohn\u2019s Disease: A Post Hoc Analysis of the SEAVUE Trial"],"prefix":"10.1093","volume":"31","author":[{"given":"Dhruv","family":"Ahuja","sequence":"first","affiliation":[{"name":"Department of Medicine, Indira Gandhi Hospital , New Delhi ,","place":["India"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7284-8735","authenticated-orcid":false,"given":"Sama","family":"Anvari","sequence":"additional","affiliation":[{"name":"Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute; McMaster University , Hamilton, ON ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily C L","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute; McMaster University , Hamilton, ON ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parambir","family":"Dulai","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Northwestern University , Chicago, IL ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John K","family":"Marshall","sequence":"additional","affiliation":[{"name":"Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute; McMaster University , Hamilton, ON ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vipul","family":"Jairath","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Gastroenterology, Western University , London, ON ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2088-091X","authenticated-orcid":false,"given":"Walter","family":"Reinisch","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna , W\u00e4hringer G\u00fcrtel 18-20, Vienna ,","place":["Austria"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1536-8436","authenticated-orcid":false,"given":"Neeraj","family":"Narula","sequence":"additional","affiliation":[{"name":"Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute; McMaster University , Hamilton, ON ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"issue":"4","key":"2025112116470172600_CIT0001","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/ibd\/izx100","article-title":"Quality of life in inflammatory bowel disease: a systematic review and meta-analyses\u2014Part I","volume":"24","author":"Knowles","year":"2018","journal-title":"Inflamm Bowel Dis."},{"issue":"1","key":"2025112116470172600_CIT0002","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1053\/j.gastro.2020.03.039","article-title":"Deep remission at 1 year prevents progression of early Crohn\u2019s disease","volume":"159","author":"Ungaro","year":"2020","journal-title":"Gastroenterology."},{"issue":"6","key":"2025112116470172600_CIT0003","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.cgh.2019.12.020","article-title":"How do we treat inflammatory bowel diseases to aim for endoscopic remission","volume":"18","author":"Dulai","year":"2020","journal-title":"Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc"},{"issue":"5","key":"2025112116470172600_CIT0004","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology."},{"issue":"7","key":"2025112116470172600_CIT0005","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1136\/gut.30.7.983","article-title":"Development and validation of an endoscopic index of the severity for Crohn\u2019s disease: a prospective multicentre study. Groupe d\u2019Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID)","volume":"30","author":"Mary","year":"1989","journal-title":"Gut."},{"issue":"4","key":"2025112116470172600_CIT0006","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/s0016-5107(04)01878-4","article-title":"Development and validation of a new, simplified endoscopic activity score for Crohn\u2019s disease: the SES-CD","volume":"60","author":"Daperno","year":"2004","journal-title":"Gastrointest Endosc."},{"issue":"13","key":"2025112116470172600_CIT0007","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1016\/j.cgh.2019.04.040","article-title":"Should we divide Crohn\u2019s disease into ileum-dominant and isolated colonic diseases","volume":"17","author":"Dulai","year":"2019","journal-title":"Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc"},{"issue":"8","key":"2025112116470172600_CIT0008","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.14309\/ajg.0000000000000617","article-title":"Ileal and rectal ulcer size affects the ability to achieve endoscopic remission: a post hoc analysis of the SONIC trial","volume":"115","author":"Narula","year":"2020","journal-title":"Am J Gastroenterol."},{"issue":"3","key":"2025112116470172600_CIT0009","doi-asserted-by":"publisher","first-page":"183","DOI":"10.4103\/1319-3767.182455","article-title":"Implementation of the simple endoscopic activity score in crohn\u2019s disease","volume":"22","author":"Koutroumpakis","year":"2016","journal-title":"Saudi J Gastroenterol"},{"issue":"6","key":"2025112116470172600_CIT0010","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1136\/gutjnl-2020-323799","article-title":"Predicting endoscopic remission in Crohn\u2019s disease by the modified multiplier SES-CD (MM-SES-CD)","volume":"71","author":"Narula","year":"2022","journal-title":"Gut."},{"issue":"7","key":"2025112116470172600_CIT0011","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1093\/ecco-jcc\/jjac018","article-title":"Categorising endoscopic severity of Crohn\u2019s disease using the modified multiplier SES-CD [MM-SES-CD]","volume":"16","author":"Narula","year":"2022","journal-title":"J Crohns Colitis."},{"issue":"9","key":"2025112116470172600_CIT0012","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1136\/gutjnl-2015-309903","article-title":"IOIBD technical review on endoscopic indices for Crohn\u2019s disease clinical trials","volume":"65","author":"Vuitton","year":"2016","journal-title":"Gut."},{"issue":"8","key":"2025112116470172600_CIT0013","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/j.cgh.2024.02.009","article-title":"Defining endoscopic remission in Crohn\u2019s disease: MM-SES-CD and SES-CD thresholds associated with low risk of disease progression","volume":"22","author":"Narula","year":"2024","journal-title":"Clin Gastroenterol Hepatol: Off Clin Pract J Am Gastroenterol Assoc"},{"issue":"10342","key":"2025112116470172600_CIT0014","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1016\/S0140-6736(22)00688-2","article-title":"Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn\u2019s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial","volume":"399","author":"Sands","year":"2022","journal-title":"Lancet (London, England)"},{"key":"2025112116470172600_CIT0015","doi-asserted-by":"crossref","DOI":"10.31478\/201906b","article-title":"Individual patient-level data sharing for continuous learning: a strategy for trial data sharing","author":"Kuntz","year":"2019","journal-title":"NAM Perspectives"},{"issue":"1","key":"2025112116470172600_CIT0016","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/apt.13001","article-title":"A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn\u2019s disease activity","volume":"41","author":"Khanna","year":"2015","journal-title":"Aliment Pharmacol Ther."},{"issue":"5","key":"2025112116470172600_CIT0017","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1053\/j.gastro.2013.08.010","article-title":"Validation of endoscopic activity scores in patients with Crohn\u2019s disease based on a post hoc analysis of data from SONIC","volume":"145","author":"Ferrante","year":"2013","journal-title":"Gastroenterology."},{"issue":"Supplement_1","key":"2025112116470172600_CIT0018","doi-asserted-by":"publisher","first-page":"i1516","DOI":"10.1093\/ecco-jcc\/jjad212.0950","article-title":"Targeting MM-SES-CD &lt; 22.5 for endoscopic improvement is feasible in a clinical trial of Crohn\u2019s disease: a post-hoc analysis of SEAVUE","volume":"18","author":"Narula","year":"2024","journal-title":"J Crohns Colitis."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izaf137\/63629076\/izaf137.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/11\/3103\/63629076\/izaf137.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/31\/11\/3103\/63629076\/izaf137.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T21:47:09Z","timestamp":1763761629000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/31\/11\/3103\/8178734"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":18,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,6,30]]},"published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izaf137","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"type":"print","value":"1078-0998"},{"type":"electronic","value":"1536-4844"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,6,30]]}}}